EFG International AG Acquires New Position in DexCom, Inc. $DXCM

EFG International AG bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the second quarter, HoldingsChannel.com reports. The firm bought 13,201 shares of the medical device company’s stock, valued at approximately $889,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DXCM. Geode Capital Management LLC raised its holdings in DexCom by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock valued at $727,842,000 after acquiring an additional 42,411 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of DexCom by 6.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,999,057 shares of the medical device company’s stock worth $530,897,000 after purchasing an additional 516,526 shares during the last quarter. Norges Bank acquired a new stake in shares of DexCom during the fourth quarter worth $483,356,000. Invesco Ltd. grew its position in shares of DexCom by 14.8% in the fourth quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company’s stock valued at $352,781,000 after purchasing an additional 686,228 shares during the period. Finally, CIBC Private Wealth Group LLC grew its position in shares of DexCom by 7.6% in the fourth quarter. CIBC Private Wealth Group LLC now owns 3,128,114 shares of the medical device company’s stock valued at $207,613,000 after purchasing an additional 220,313 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Trading Down 0.2%

DXCM stock opened at $88.96 on Thursday. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The company has a market cap of $33.57 billion, a price-to-earnings ratio of 35.16, a PEG ratio of 1.50 and a beta of 1.41. The business has a fifty day simple moving average of $78.50 and a 200-day simple moving average of $71.33. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $92.59.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The firm had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. During the same quarter last year, the firm earned $0.48 earnings per share. The firm’s revenue for the quarter was up 13.1% compared to the same quarter last year. On average, equities research analysts expect that DexCom, Inc. will post 2.64 EPS for the current year.

Analysts Set New Price Targets

DXCM has been the subject of several analyst reports. Citigroup reiterated a “buy” rating and issued a $88.00 target price (up from $84.00) on shares of DexCom in a research note on Friday, July 31st. Canaccord Genuity Group set a $90.00 price target on DexCom and gave the company a “buy” rating in a report on Monday, August 3rd. Benchmark lifted their price target on DexCom from $77.00 to $82.00 and gave the company a “buy” rating in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft started coverage on shares of DexCom in a research note on Tuesday, June 23rd. They set a “buy” rating and a $86.00 price objective for the company. Finally, UBS Group set a $96.00 price objective on shares of DexCom and gave the stock a “buy” rating in a report on Tuesday, July 28th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average target price of $88.71.

Insider Transactions at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.55, for a total transaction of $128,435.00. Following the transaction, the executive vice president directly owned 106,353 shares of the company’s stock, valued at $8,034,969.15. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the business’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the sale, the insider owned 328,970 shares of the company’s stock, valued at approximately $25,106,990.40. This represents a 7.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 73,035 shares of company stock valued at $5,446,673. 0.28% of the stock is currently owned by company insiders.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.